MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively. MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity.
性状
Solid
IC50 & Target[1][2]
IC50: 9.1 nM (hMAGL) and 2.1 nM (2-AG)
体外研究(In Vitro)
MJN110 (0.01-1000 nM; 4 hours) has the primary serine hydrolase target, hMAGL, with an IC50 of ~1 nM and 10- and 100-fold selectivity windows over ABHD6 and LYPLA1/2, respectively.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis
Cell Line:
Human-derived PC3 cells
Concentration:
0.01, 0.1, 1, 10, 100, 1000 nM
Incubation Time:
4 hours
Result:
HMAGL acted as the primary serine hydrolase target with an IC50 of ~1 nM.
体内研究(In Vivo)
MJN110 (i.p.; 0.0818 mg/kg; twice daily for 5.5 days) reverses chronic constriction injury (CCI)-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner. The respective ED50 value (95% confidence limits) is 0.430 (0.233-0.793) mg/kg.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Male C57BL/6J mice ranged from 18 to 35 g
Dosage:
0.0818 mg/kg
Administration:
I.p.; twice daily for 5.5 days
Result:
Reversed CCI-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner.